ClinicalTrials.gg
Active, not recruitingNCT06987695MARITIME-3-JUpdated Dec 17, 2025

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Obesity Disease, sponsored by Amgen. Active, not recruiting at 30 sites in Japan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing maridebart cafraglutide in Overweight — 8 open to participants now, 15 under way, 10 of them phase 3. maridebart cafraglutide · Overweight.

Enrollment
13th of 25
279 · median 279
Started
2025
with 9 others
Phase 3
10 of 25
5 open now
Primary completion
2027-04
later than 4 of 14 live
Registered
5th of 25
by date
Lead sponsor
25 of 25
Amgen

Among the 25 studies testing maridebart cafraglutide in Overweight, this one is the 13th largest by enrollment, is one of 10 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 5th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

8 of the 25 studies testing maridebart cafraglutide in Overweight are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing maridebart cafraglutide in Overweight, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.

03

Conditions studied

  • Obesity Disease

Keywords

  • Overweight
  • BMI
  • Body weight
  • Maridebart cafraglutide
  • Chronic weight management
  • MariTide
  • Type 2 Diabetes Mellitus
  • T2DM
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
  • (BMI) ≥ 35 kg/m\^2 at screening with a current diagnosis of at least 1 of the weigh-related comorbidities specified in the Japan Society for the Study of Obesity (JASSO) guideline OR BMI ≥ 27 kg/m\^2 to \< 35 kg/m\^2 at screening, with a current diagnosis of at least 2 of the weight-related comorbidities specified in the JASSO guideline.
  • For both BMI categories, at least 1 of the weight-related comorbidities must be hypertension, dyslipidemia, or T2DM according to the definitions below:

    1. hypertension: treated, or with SBP ≥ 140 mmHg, or DBP ≥ 90 mmHg at screening.
    2. dyslipidemia: treated, or with LDL > 140 mg/dL (3.6 mmol/L), or triglycerides ≥ 150 mg/dL (1.7 mmol/L), or non-HDL cholesterol > 170 mg/dL (4.4 mmol/L) or HDL \< 40 mg/dL (1.0 mmol/L) at screening.
    3. T2DM: diagnosed ≥ 180 days before screening, and treated with diet and exercise alone and/or a stable treatment for at least 90 days before screening with up to 3 oral glucose-lowering medications (as per local labeling) (except for glucagon-like peptide-1 receptor agonists [GLP-1RA] and dipeptidyl peptidase-4 [DPP-4] inhibitors), and have a ≥ 7% and ≤ 10% (53-86 mmol/mol) at screening.
  • In the opinion of the investigator, well-motivated and willing to:

    1. Follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice, maintain a study log(s)/diary(ies), and complete required study visits and questionnaires.
    2. Perform self-monitoring blood glucose (SMBG) per protocol (only for participants with T2DM).

Exclusion criteria

Exclusion Criteria:

  • Obesity induced by other endocrinological disorders or monogenetic or syndromic forms of obesity.
  • Self-reported change in body weight > 5 kg within 90 days before screening.
  • Previous or planned (during the study) surgical, endoscopic, or device-based treatment for obesity.
  • For participants without diabetes at screening, type 1 or 2 diabetes mellitus or any other types of diabetes mellitus (except history of gestational diabetes).
  • For participants with T2DM at screening, any other type(s) of diabetes mellitus except T2DM.
  • History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.
  • Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).
  • History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.
  • Lifetime history of suicide attempt.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Maridebart Cafraglutide High Dose

    Participants will receive maridebart cafraglutide high dose subcutaneously (SC) for 72 weeks.

    Drug: Maridebart cafraglutide

  • Experimental
    Maridebart Cafraglutide Medium Dose

    Participants will receive maridebart cafraglutide medium dose SC for 72 weeks.

    Drug: Maridebart cafraglutide

  • Experimental
    Maridebart Cafraglutide Low Dose

    Participants will receive maridebart cafraglutide low dose SC for 72 weeks.

    Drug: Maridebart cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC for 72 weeks.

    Drug: Placebo

Interventions

  • Maridebart cafraglutide will be administered SC.

    Also known as: AMG 133, MariTide

  • DrugPlacebo

    Placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 72

    Time frame: Baseline and Week 72

  2. Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 72

    Time frame: Baseline and Week 72

Secondary outcomes

  1. Change From Baseline in Waist Circumference at Week 72

    Time frame: Baseline and Week 72

  2. Participants Achieving ≥ 10% Reduction in Body Weight from Baseline at Week 72

    Time frame: Baseline and Week 72

  3. Participants Achieving ≥ 15% Reduction in Body Weight from Baseline at Week 72

    Time frame: Baseline and Week 72

  4. Change From Baseline in Body Weight at Week 72

    Time frame: Baseline and Week 72

  5. Percent Change From Baseline in Body Weight in Participants Without Type 2 Diabetes Mellitus (T2DM) at Week 72

    Time frame: Baseline and Week 72

  6. Percent Change From Baseline in Body Weight in Participants With T2DM at Week 72

    Time frame: Baseline and Week 72

  7. Change From Baseline in Body Mass Index (BMI) at Week 72

    Time frame: Baseline and Week 72

  8. Participants Achieving ≥ 20% Reduction in Body Weight from Baseline at Week 72

    Time frame: Baseline and Week 72

  9. Change From Baseline in Visceral Fat Area (VFA) at Week 72

    Time frame: Baseline and Week 72

  10. Participants Achieving VFA < 100 cm^2 in VFA at Week 72

    Time frame: Week 72

  11. Percent Change From Baseline in Fasting Total Cholesterol at Week 72

    Time frame: Baseline and Week 72

  12. Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (non-HDL-C) at Week 72

    Time frame: Baseline and Week 72

  13. Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Week 72

    Time frame: Baseline and Week 72

  14. Percent Change From Baseline in Fasting Triglycerides at Week 72

    Time frame: Baseline and Week 72

  15. Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 72

    Time frame: Baseline and Week 72

  16. Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Week 72

    Time frame: Baseline and Week 72

  17. Change From Baseline in Systolic Blood Pressure (SBP) at Week 72

    Time frame: Baseline and Week 72

  18. Change From Baseline in Diastolic Blood Pressure (DBP) at Week 72

    Time frame: Baseline and Week 72

  19. Change From Baseline in Fasting Plasma Glucose at Week 72

    Time frame: Baseline and Week 72

  20. Percent Change From Baseline in Fasting Insulin at Week 72

    Time frame: Baseline and Week 72

  21. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72

    Time frame: Baseline and Week 72

  22. Percentage of Participants with a Change from Baseline in Glycemic Status at Week 72 for Participants Without T2DM at Baseline

    Glycemic status was categorized as: * normoglycemic (fasting plasma glucose \< 100 mg/dL and HbA1c \< 5.7%, in absence of T2DM diagnosis), * prediabetes (fasting plasma glucose 100 - 125 mg/dL or HbA1c 5.7% - 6.4% in the absence of a T2DM diagnosis), * or, T2DM (fasting plasma glucose ≥ 126 mg/dL and HbA1c ≥6.5%).

    Time frame: Baseline and Week 72

  23. Participants With T2DM Achieving HbA1c < 7% at Week 72

    Time frame: Week 72

  24. Participants With T2DM Achieving HbA1c ≤ 6.5% at Week 72

    Time frame: Week 72

  25. Participants With T2DM Achieving HbA1c < 5.7% at Week 72

    Time frame: Week 72

  26. Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Physical Function Domain Score at Week 72

    The SF-36v2 Acute Physical Function domain score measures an individual's ability to perform daily physical activities, such as walking and climbing stairs, over the past week. It includes 10 items scored on a 3-point Likert scale, with raw scores transformed to a 0-100 scale. Higher scores indicate better physical functioning and fewer limitations due to physical health.

    Time frame: Baseline and Week 72

  27. Change from Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72

    The IWQOL-Lite-CT is a 20-item questionnaire designed to assess the impact of weight on quality of life in clinical trials. Items are scored on a 5-point Likert scale, with raw scores transformed to a 0-100 scale, where higher scores indicate better quality of life and less weight-related impact.

    Time frame: Baseline and Week 72

  28. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Week 84

  29. Number of Participants Experiencing Serious Adverse Events

    Time frame: Up to Week 84

  30. Plasma Concentration of Maridebart Cafraglutide at Week 72

    Time frame: Week 72

07

Study locations

30 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 127 industry-sponsored phase 3 interventional studies under Overweight, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's planned 22 months is close to that.

Counting every sponsor, half of 136 studies reached it within 21 months; a quarter within 17 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 23, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Apr 27, 2027
CompletionEst.
Jul 21, 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06987695
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Jun 13, 2025
Primary completion
Apr 27, 2027 (estimated)
Completion
Jul 21, 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion